MedPath

Prognostic Value of Biomarkers in Polyneuropathy.

Recruiting
Conditions
Polyneuropathies
Registration Number
NCT06044662
Lead Sponsor
Rigshospitalet, Denmark
Brief Summary

Biomarkers for prognosis of patients with polyneuropathy.

Detailed Description

AIM: To investigate biomarkers' use as a prognostic tool in polyneuropathy patients.

STUDY DESIGN: Prospective cohort study of patients with polyneuropathy. METHODS: 200 patients with polyneuropathy will be examined with physical tests, medical examination, questionnaires, and blood biomarkers at baseline and at 1-year follow-up, and 2-year follow-up.

ANALYSIS: The investigators will calculate the odds of disease progression after 2 years depending on biomarkers levels at baseline using multiple logistic regression with sex and age adjustment. Diagnostic performance of the physical tests and biomarkers for prediction of disease progression will be assessed by Receiver Operating Characteristic Curve analysis with the area under the curve.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
200
Inclusion Criteria
  • Minimum 18 years old.
  • Diagnosed with polyneuropathy, confirmed by nerve conduction study.
  • Can read and understand Danish.
Exclusion Criteria
  • Inability to perform physical tests due to comorbidity not associated to the patient's polyneuropathy.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Disease Severity2 years

Primary outcome is disease severity

Secondary Outcome Measures
NameTimeMethod
Patient Reported Outcomes (PROMs)2 years

Secondary outcome is patient reported outcomes.

Trial Locations

Locations (1)

Copenhagen Neuromuscular Center, Department of Neurology, Rigshospitalet

🇩🇰

Copenhagen, Denmark

Copenhagen Neuromuscular Center, Department of Neurology, Rigshospitalet
🇩🇰Copenhagen, Denmark
Tina Dysgaard, Dr.mee
Contact
±45 35458077
Tina.dysgaard@regionh.dk
Louise Kodal, MD
Contact
Louise.boensdorff.sloth.01@regionh.dk

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.